NICE recommends ustekinumab for psoriatic arthritis
The National Institute for Health and Care Excellence (NICE) has issued draft guidance for consultation recommending that use of ustekinumab (Stelara; Janseen-Cilag) on the NHS for the treatment of psoriatic arthritis in specific circumstances. NICE rejected the drug in May 2014 but, following the introduction of a patient access scheme, has proposed a reversal of this decision. Further information can be found on the NICE website under technology appraisal number 313. Comments must be submitted by 7 January 2015.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067422
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com